Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC5107 in Primary Humoral Immunodeficiency
NCT02783482Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Oct 2016
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in Primary Humoral Immunodeficiency, sponsored by GC Biopharma. Primary endpoints: Incidence of Acute Serious Bacterial Infections at 1 year and Proportion of Infusions With Temporally Associated Adverse Events at 72 hours. Started Oct 2016; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Primary Humoral Immunodeficiency
Beyond the preview
Go deeper on NCT02783482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783482.